You are here

Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients

Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients Aude G. Chapuis1,*, Gunnar B. Ragnarsson1,*,†, Hieu N. Nguyen1, Colette N. Chaney1, Jeffrey S. Pufnock1,‡, Thomas M. Schmitt1, Natalie Duerkopp1, Ilana M. Roberts1,§, Galina L. Pogosov2, William Y. Ho1,¶, Sebastian Ochsenreither1,||, Matthias Wölfl1,**, Merav Bar2, Jerald P. Radich2, Cassian Yee1,††‡‡ and Philip D. Greenberg1,3,‡‡

Chapuis1,*, Gunnar B. Ragnarsson1,*,†, Hieu N. Nguyen1, Colette N. Chaney1, Jeffrey S. Pufnock1,‡, Thomas M. Schmitt1, Natalie Duerkopp1, Ilana M. Roberts1,§, Galina L. Pogosov2, William Y. Ho1,¶, Sebastian Ochsenreither1,||, Matthias Wölfl1,**, Merav Bar2, Jerald P. Radich2, Cassian Yee1,††‡‡ and Philip D. Greenberg1,3,‡‡


Relapse remains a leading cause of death after allogeneic hematopoietic cell transplantation (HCT) for patients with high-risk leukemias. The potentially beneficial donor T cell–mediated graft-versus-leukemia (GVL) effect is often mitigated by concurrent graft-versus-host disease (GVHD). Providing T cells that can selectively target Wilms tumor antigen 1 (WT1), a transcription factor overexpressed in leukemias that contributes to the malignant phenotype, represents an opportunity to promote antileukemic activity without inducing GVHD.


http://stm.sciencemag.org/content/5/174/174ra27.abstract